Evaluation of the Bioequivalence and Pharmacokinetics of Two Lisinopril Tablet Formulations after Single Oral Administration in Healthy Volunteers

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 1, 2004, Pages 15-19

  Georgarakis, Manolis ^a   Tsakalof, Andreas ^b   Zougrou, Fotini ^a   Kontopoulos, Georgios ^c   Tsiptsios, Iakovos ^d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b The Ormylia Foundation   (Greece)

^c Cardiologist   (Greece)

^d Hospital St Paulus   (Greece)

Author keywords

Adicanil , bioequivalence studies, clinical pharmacokinetics; Angiotensin converting enzyme inhibitor; CAS 76547 98 3; Lisinopril, bioequivalence studies, clinical pharmacokinetics

Indexed keywords

ADICANIL; LISINOPRIL;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SCREENING; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZATION; STATISTICAL ANALYSIS;

EID: 0742287138     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296931     Document Type: Article

References (11)

1. Biollaz, J., Burnier, M., Turini, G. A. et al., Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enxyme activity and response to angiotensin I. Clin. Pharmacol Ther. 29, 665 (1981).
2. Brunner, D.B., Desponds, G., Biollaz, J. et al., Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the resin system in healthy volunteers. Br. J. Clin. Pharmacol. 11, 461 (1981)
3. Millar, J.A., Derkx, F.H.M., McLean, K. et al., Pharmacodynamics of converting enzyme inhibition:the cardiovascular, endocrine and autonomic eggects of MK 421 (enalapril) and MK 521. Br. J. Clin. Pharmacol. 14, 347 (1982)
4. Beermann, B., Till, A., Gomez, H. et al., Biopharm. Drug Dispos. 10, 397 (1989)
5. Beermann, B., Pharmacokinetics of Lisinopril. Am. J. Med. 85 (Suppl. 3B), 25 (1988)
6. Mojaverian, P., Rocci, M., Vlasses, P. et al., Effect of food on the bioavailiability of lisinopril, a Nonsulfhydryl Angiotensin-Converting Enzyme Inhibitor. J. Pharm. Sci. 75, 395 (1986)
7. Bellissant, E., Chau, N., Giudicelli, J., Pharmacokinetic- Pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. J. Cardiovasc. Pharmacol. 28, 470 (1996)
8. Bellissant, E., Thuillez, C., Richer, C. et al., Noninvasive assessment of regional arteriolar and arterial dilating properties of lisinopril in healthy volunteers. J. Cardiovasc. Pharmacol. 24, 500 (1994)
9. Tsakalof, A., Bairaktari, K., Georgarakis, M., Development of liquid chromatography-mass spectrometry method for monitoring the antiotensin- converting enzyme inhibitor lisinopril in serum, J. Chromatogr. B 783, 425 (2003)
10. Chow, S., Liu, P., Design and Analysis of Bioavailability and Bioequivalence Studies, Marcel Dekker, New York (1992)
11. Committee for proprietary medicinal products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. London (1998)